Tecentriq 1200mg/20mL (Atezolizumab)

Tecentriq 1200mg/20mL contains Atezolizumab, a monoclonal antibody and immune checkpoint inhibitor. It targets the PD-L1 protein, helping the immune system recognize and attack certain cancer cells.

Key Information

• Active Ingredient: Atezolizumab
• Strength: 1200mg/20mL
• Form: Solution for intravenous infusion
• Uses: Used for certain cases of non-small cell lung cancer, small cell lung cancer, liver cancer, urothelial cancer, triple-negative breast cancer, melanoma and alveolar soft part sarcoma.
• Administration: Administered through intravenous infusion by a qualified healthcare professional.
• Common Side Effects: Fatigue, decreased appetite, nausea, cough and shortness of breath may occur.
• Important: Tecentriq can cause immune-mediated reactions where the immune system attacks healthy organs. Medical monitoring is required during treatment.

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare professional before starting or changing any medication.